Infectious Disease Clinical Trials
Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients
With Necrotizing Soft Tissue Infections (ACCUTE)
Researchers want to find out if a single treatment of the investigational
drug, AB103, can better help people with necrotizing soft tissue infections
improve their condition, including decreasing the number of surgeries
and improving organ dysfunction, than when using standard treatment alone.
Principal Investigator: Hollis O’Neal, MD
Status: Currently recruiting participants.
Click here for additional information about this clinical trial.